What is the appropriate dosing regimen for a patient taking Strattera (Atomoxetine) 40mg daily?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 20, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Strattera (Atomoxetine) 40mg Daily Dosing

For patients currently on 40mg daily, this represents the standard starting dose for adults and adolescents over 70kg, and should be maintained for a minimum of 3 days before considering any dose increase. 1

Initial Dosing and Titration Schedule

  • Start at 40mg once daily (single morning dose or divided into morning and late afternoon/evening doses) for adults and patients over 70kg 1
  • Maintain this initial 40mg dose for at least 3 days before increasing to assess tolerability 1
  • After the minimum 3-day period, increase to the target dose of 80mg daily (either as single morning dose or divided doses) 1
  • Wait an additional 2-4 weeks at 80mg before considering further increases 1
  • Maximum dose is 100mg daily for adults and adolescents over 70kg 1

Critical Timing Considerations

  • Allow 1-2 weeks at each dose level to properly assess tolerability before increasing, as recommended by the American Academy of Child and Adolescent Psychiatry 2
  • Full therapeutic effect requires 6-12 weeks, unlike stimulants which work within hours—set appropriate patient expectations 2
  • Increasing doses too rapidly risks behavioral activation/agitation (motor restlessness, insomnia, impulsiveness, aggression), particularly in younger patients 2

Dosing Adjustments for Special Circumstances

When taking CYP2D6 inhibitors (paroxetine, fluoxetine, quinidine, duloxetine):

  • Maintain 40mg for 4 weeks minimum before increasing 1
  • Only increase to 80mg if symptoms fail to improve AND the initial dose is well tolerated 1
  • These medications significantly increase atomoxetine exposure and half-life 3

Hepatic impairment:

  • Moderate impairment (Child-Pugh Class B): Reduce all doses to 50% of normal 1
  • Severe impairment (Child-Pugh Class C): Reduce all doses to 25% of normal 1

Administration Guidelines

  • Can be taken with or without food 1
  • Single daily dosing is as effective as divided dosing and may improve adherence 4
  • Swallow capsules whole—do not open or crush 1
  • Can be discontinued without tapering 1

Monitoring Requirements

  • Measure blood pressure and heart rate at baseline, after each dose adjustment, and at least monthly during maintenance 2, 3
  • Monitor for suicidality closely during the first few months and at times of dose changes (FDA black box warning) 2, 5
  • Watch for hepatic symptoms (abdominal pain, jaundice, elevated transaminases)—discontinue immediately if these occur 3
  • Monitor for behavioral activation especially in the first 24-48 hours after dose changes 6

Common Adverse Effects to Anticipate

  • Gastrointestinal effects (nausea, vomiting, abdominal pain) are most common and typically transient 2, 7
  • Decreased appetite and initial weight loss may occur 2
  • Somnolence and fatigue can occur, particularly if dose is increased too rapidly 2
  • Cardiovascular changes (modest increases in heart rate and blood pressure) are generally well tolerated 5

Key Clinical Pitfalls to Avoid

  • Do not exceed 100mg daily—no data support increased effectiveness at higher doses 1
  • Do not increase doses more frequently than every 1-2 weeks—this increases risk of behavioral activation 2
  • If side effects occur, return to the previous well-tolerated dose rather than discontinuing entirely 2
  • Do not expect immediate results—counsel patients that full effect takes 6-12 weeks 2

References

Guideline

Risks of Increasing Strattera Dosage

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Combination Therapy with Strattera and Cymbalta

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Combination Therapy for ADHD with Strattera and Vyvanse

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.